|Title:||In vitro synergistic interaction between DTA0100 and radiation in human cancercell lines||Authors:||Bordón Rodríguez, Elisa de los Reyes
León, Leticia G.
Lara, Pedro C.
Padrón, José M.
|UNESCO Clasification:||32 Ciencias médicas||Keywords:||Anticancer drugs
Mechanism of action
Median drug effect
|Issue Date:||2012||Publisher:||1871-5206||Journal:||Anti-Cancer Agents in Medicinal Chemistry||Abstract:||DTA0100 is a new catalytic inhibitor of the human DNA topoisomerase IIα that induces G2/M phase cell cycle arrest in human solid tumor cells lines from various malignancies. In our study, we investigated the effectiveness of the combined treatment of ionizing radiation with DTA0100 on the survival of three representative human solid tumor cell lines: HeLa (cervix), WiDr (colon) and SW1573 (non-small cell lung cancer). The concomitant treatment of DTA0100 and irradiation showed a synergistic and antagonistic effect in the three cell lines tested. A synergistic cytotoxic effect of the combination of DTA0100 and radiation was confirmed by the median drug effect analysis method. It was found that in those protocols where the drug was administered after radiation the most synergistic effect was achieved. Our study constitutes the first in vitro evidence for synergistic effects between DTA0100 and radiation. This combination therapy might thus be expected to be more effective than either treatment alone in patients with cervical, colon and non-small cell lung cancer cells.||URI:||http://hdl.handle.net/10553/43847||ISSN:||1871-5206||DOI:||10.2174/187152012802650057||Source:||Anti-Cancer Agents in Medicinal Chemistry [ISSN 1871-5206], v. 12, p. 988-993|
|Appears in Collections:||Artículos|
checked on Feb 21, 2021
checked on Feb 22, 2021
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.